NCT06021145View on ClinicalTrials.gov

Effectiveness of Empagliflozin Added to Automated Insulin Delivery (AID) Systems in Adults With Type 1 Diabetes With Sub-optimal Glycemic Outcomes

PHASE4RecruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

April 2, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions
Type 1 Diabetes
Interventions
DRUG

Empagliflozin

26-week use of automated insulin delivery system with empagliflozin (2.5 mg daily) in individuals with suboptimal time in range.

DRUG

Placebo

26-week use of automated insulin delivery system with placebo (daily) in individuals with suboptimal time in range.

Trial Locations (1)

H4A 3J1

RECRUITING

McGill University Health Centre, Montreal

All Listed Sponsors
collaborator

Diabetes Canada

OTHER

lead

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER